No. of Recommendations: 0
Dendreon is probably lost money for awhile longer and sinking more in may take a long time to pay off. They still are not profitable from Provenge--marketing this drug looks like it's killing them. The problem is the uphill battle the drug reps may be facing pushing this on docs. The marketing spending is big and the results have been poor. Unfortunately there is now an attractive competitor at a much lower initial outlay of cash==Zytiga from JNJ

All this would be OK if Dendreon had anything like a ripe pipeline. You could afford to wait for Provenge to catch fire but there is basically nothing cooking. There are a couple of things preclinical and one drug in clinical trials for solid tumors. It would take Provenge being the $2 billion blockbuster it was billed as to get the share price moving again. So far investors are disappointed and it's hard to know if Provenge is going to be as good as Dendreon forecasted. They have been wrong a lot on sales guidance
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.